Norland's X-ray device will assess fracture risk:
This article was originally published in Clinica
Norland Medical Systems has received 510(k) clearance from the FDA to market a fracture risk assessment feature on its Apollo DXA peripheral bone densitometer. Until recently, doctors could not easily predict which osteoporosis sufferers were at high risk of a bone fracture, but last year the FDA determined that manufacturers of bone density devices could offer a feature which would help. This feature is already available on Norland's pDEXA device.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.